secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001193125-23-264057
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics appoints Brendan Hannah as COO, effective Oct 24, 2023
--------------------------------------------------------------------------

- Brendan Hannah, age 38, appointed COO; continues as Chief Business Officer and principal financial/accounting officer.
- Granted option to purchase 75,000 shares at $0.99, vesting over 48 months from Oct 23, 2023.
- Served as Chief Business Officer since May 2022; previously COO of Novosteo Inc.
- No family relationships or transactions requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/0001193125-23-264057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/d563197d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-264057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer